[Hopespringpcsg] Fw: ClarityDX Prostate - a new biomarker for prostate cancer

[WILLIAM FAULKNER]

Sent from Rogers Yahoo Mail on Android 
 
   
  <!--#yiv9970944211 filtered {}#yiv9970944211 filtered {}#yiv9970944211 filtered {}#yiv9970944211 filtered {}#yiv9970944211 p.yiv9970944211MsoNormal, #yiv9970944211 li.yiv9970944211MsoNormal, #yiv9970944211 div.yiv9970944211MsoNormal {margin:0in;font-size:11.0pt;font-family:"Calibri", sans-serif;}#yiv9970944211 a:link, #yiv9970944211 span.yiv9970944211MsoHyperlink {color:#0563C1;text-decoration:underline;}#yiv9970944211 span.yiv9970944211xn-person {}#yiv9970944211 span.yiv9970944211EmailStyle20 {font-family:"Calibri", sans-serif;color:windowtext;}#yiv9970944211 .yiv9970944211MsoChpDefault {font-size:10.0pt;}#yiv9970944211 filtered {}#yiv9970944211 div.yiv9970944211WordSection1 {}-->
Please distribute.

  

On Feb 11th, your members are all invited to participate in a joint Brampton/Oakville-Mississauga zoom presentation on “technological advanced in prostate cancer screening” (see Zoom link information below).

  

Title: 
Technological Advances in Prostate Cancer Screening

Objectives: 

1. Understand the need for improvement of current prostate cancer screening guidelines in Canada

2. Understand the necessity & benefit of adjunctive testing strategies in prostate cancer screening 

3. Increase awareness & understanding of ClarityDX Prostate

  

PSA is the only prostate cancer biomarker routinely used by urologists. However, PSA alone does not distinguish well between cancer and benign prostatic hyperplasia or between indolent and aggressive cancers, potentially leading to overtreatment, especially unnecessary biopsies. 

  

ClarityDX Prostate uses clinical and blood-based biomarkers to determine a patient’s risk of having clinically significant prostate cancer

ClarityDX Prostate is a decision support tool that accurately predicts clinically significant (aggressive) prostate cancer after an abnormal PSA or a suspicion of prostate cancer.  https://www.nanosticsdx.com/claritydx-prostate/

  

"This study shows that ClarityDX Prostate is accurate at predicting if the patient has grade group 2 and above prostate cancer," said Dr. Eric Hyndman, Urologist and Chief Medical Officer at Nanostics. "Using this as an adjunctive test after PSA screening will give physicians more information to help decide if their patient should undergo a prostate biopsy or not."

  

Time: Feb 11, 2025 07:30 PM Eastern Time (US and Canada)

       

Join Zoom Meeting https://us02web.zoom.us/j/82819100419?pwd=TFhVUTZBQTNhZVRRSkE0VU9EM0ordz09

  

Meeting ID: 828 1910 0419; Passcode: 091248

  
  
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://artsservices.uwaterloo.ca/pipermail/hopespringpcsg/attachments/20250131/4082ead4/attachment.htm>